October 29, 2009Open Access

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Key Points

Key points are not available for this paper at this time.

Abstract

These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Finn et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d8d1bff39dfae3cad180e0 — DOI: https://doi.org/10.1186/bcr2419

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

RB in Breast Cancer: The Crossroads of Tumorigenesis and Treatment· 2007 · 109 citations
<i>In vitro</i> and <i>in vivo</i> antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)· 2002 · 363 citations
Expression and amplification of cyclin genes in human breast cancer.· 1993 · 675 citations
Cell-cycle targeted therapies· 2003 · 246 citations
Control of the cell cycle and apoptosis· 1999 · 215 citations

Authors

Richard S. Finn

Judy Dering

Dylan Conklin

Journals

Breast Cancer Research

Actions

Institutions

University of California, Los Angeles

Pfizer (United States)

Pfizer (Italy)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion